

# Patrick S Ward

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/687904/publications.pdf>

Version: 2024-02-01

19  
papers

16,211  
citations

430754

18  
h-index

794469

19  
g-index

19  
all docs

19  
docs citations

19  
times ranked

19469  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. <i>Nature</i> , 2009, 462, 739-744.	13.7	3,315
2	Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate. <i>Cancer Cell</i> , 2012, 21, 297-308.	7.7	2,617
3	Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. <i>Cancer Cell</i> , 2010, 18, 553-567.	7.7	2,328
4	The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting $\alpha$ -Ketoglutarate to 2-Hydroxyglutarate. <i>Cancer Cell</i> , 2010, 17, 225-234.	7.7	1,754
5	IDH mutation impairs histone demethylation and results in a block to cell differentiation. <i>Nature</i> , 2012, 483, 474-478.	13.7	1,693
6	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. <i>Nature</i> , 2012, 483, 479-483.	13.7	1,668
7	Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of $\alpha$ -ketoglutarate to citrate to support cell growth and viability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 19611-19616.	3.3	851
8	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. <i>Nature</i> , 2010, 465, 966-966.	13.7	360
9	Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 6904-6909.	3.3	323
10	Signaling in Control of Cell Growth and Metabolism. <i>Cold Spring Harbor Perspectives in Biology</i> , 2012, 4, a006783-a006783.	2.3	237
11	DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. <i>Cell Reports</i> , 2014, 9, 1841-1855.	2.9	237
12	Identification of additional IDH mutations associated with oncometabolite R( $\alpha$ )-2-hydroxyglutarate production. <i>Oncogene</i> , 2012, 31, 2491-2498.	2.6	172
13	Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. <i>Genes and Development</i> , 2013, 27, 1974-1985.	2.7	165
14	The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization. <i>Journal of Biological Chemistry</i> , 2013, 288, 3804-3815.	1.6	141
15	Induction of sarcomas by mutant IDH2. <i>Genes and Development</i> , 2013, 27, 1986-1998.	2.7	135
16	Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2017, 7, 494-505.	7.7	94
17	Cyclic AMP triggers glucagon-like peptide-1 secretion from the GLUTag enteroendocrine cell line. <i>Diabetologia</i> , 2007, 50, 2181-2189.	2.9	67
18	SnapShot: Cancer Metabolism Pathways. <i>Cell Metabolism</i> , 2013, 17, 466-466.e2.	7.2	43

#	ARTICLE	IF	CITATIONS
19	Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate. <i>Journal of Biological Chemistry</i> , 2018, 293, 20051-20061.	1.6	11